Molecular therapy in lung cancer

Therapeutische Umschau. Revue thérapeutique
O Gautschi, D C Betticher

Abstract

Every year more than 370,000 new cases of lung cancer occur in Europe. About 70% of the patients are not curable because of local or distant spread of tumor cells. Despite the use of chemotherapy, median survival of these patients is less than one year In the last two decades, important advances in cancer research have been achieved. This led to the development of a new class of potential anti-cancer agents, selectively targeting molecules which are important for the growth and the spread of tumor cells. Focussing on lung cancer, this review presents compounds that are furthest in clinical development, covering epidermal growth factor receptor inhibitors, receptor tyrosin kinase inhibitors, anti-angiogenic agents, matrix metalloproteinase inhibitors, gene therapy and antisense therapy.

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Related Papers

Surgical Oncology
Tien HoangJoan H Schiller
The Oncologist
Roy S Herbst, Merrill S Kies
Therapeutische Umschau. Revue thérapeutique
T Egger, T Cerny
© 2022 Meta ULC. All rights reserved